In human breast cancer cell lines, the interaction between GAL-1 and β1 integrin triggered the FAK/c-Src/ERK/STAT3/survivin pathway and promoted resistance to the chemotherapeutic drug doxorubicin (84). This evidence concerns the gene GAL and breast carcinoma.